¼¼°èÀÇ ³»½Ã°æ°Ë»ç ½ÃÀåÀº 2024³â¿¡´Â 295¾ï ´Þ·¯¿¡ ´ÞÇϸç, CAGR 6.9%·Î ¼ºÀåÇϸç, 2034³â¿¡´Â 569¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ÃÀå ¼ºÀåÀº ÀÇÇÐÀÇ ¹ßÀü, ÇコÄÉ¾î ¿ì¼±¼øÀ§ º¯È, Àü ¼¼°è Áúº´ ¹ß»ý·ü Áõ°¡ µî¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ´ú ħ½ÀÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Áø´Ü ¹× Ä¡·á ¸ñÀûÀ¸·Î ³»½Ã°æ °Ë»çÀÇ »ç¿ë Áõ°¡´Â ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöÃâ Áõ°¡, Àα¸ °í·ÉÈ, ¸¸¼ºÁúȯ ¹× ¼Òȱâ ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡·Î ÀÎÇØ ½ÃÀåÀº Áö¼ÓÀûÀÎ ¸ð¸àÅÒÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¶±â Áø´ÜÀ¸·ÎÀÇ Àüȯ°ú ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ °ø°ø ¹× ¹Î°£ ÀÇ·á ȯ°æ¿¡¼ ³»½Ã°æ ½Ã¼úÀÇ Ã¤Å÷üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀº Á¤È®ÇÑ Áø´Ü, ȯÀÚÀÇ Á¶±â ȸº¹, ÀÔ¿ø ºñ¿ë Àý°¨À» À§ÇØ Ã·´Ü ³»½Ã°æ ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
2024³â¿¡´Â ³»½Ã°æ ºÎ¹®ÀÌ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ¿© 145¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. °í¼º´É ¿µ»ó Áø´Ü ¹× ½Ã¼ú Àåºñ¿¡ ´ëÇÑ ¼ö¿ä´Â ½Ã°¢Àû ¼±¸íµµ, Á¶ÀÛ¼º Çâ»ó, ·Îº¿ °øÇÐ ¹× AI¿Í °°Àº ½º¸¶Æ® ±â´ÉÀÇ ÅëÇÕ¿¡ ÈûÀÔ¾î °è¼Ó °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº Àǻ簡 ³»ÁøÇÏ´Â ¹æ½ÄÀ» º¯È½ÃÄÑ º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÛ°í À¯¿¬ÇÏ¸ç °¡º¿î ³»½Ã°æÀº ÀÌÀü¿¡´Â µµ´ÞÇÒ ¼ö ¾ø¾ú´ø ÇØºÎÇÐÀû ºÎÀ§¿¡ µµ´ÞÇÒ ¼ö ÀÖÀ¸¹Ç·Î Àü¹®ÀǵéÀÌ ¼±È£Çϰí ÀÖ½À´Ï´Ù. »ç¿ë ÆíÀǼº Çâ»ó, ȯÀÚ ºÒÆí°¨ °¨¼Ò, ¿ì¼öÇÑ ÀÓ»ó °á°ú·Î ÀÎÇØ ³»½Ã°æÀº ÀÏ»ó Áø·á¿¡¼ ³»½Ã°æÀÇ ÀÔÁö°¡ ´õ¿í °ÈµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ¿¬µµ | 2024³â |
¿¹Ãø¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 295¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 569¾ï ´Þ·¯ |
CAGR | 6.9% |
¶Ç ´Ù¸¥ ¿äÀÎÀº ¿Ü·¡ ȯÀÚ ¹× ¿Ü·¡ ȯ°æ¿¡¼ ÀÏȸ¿ë ³»½Ã°æ ±â±â¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â °¨¿° À§ÇèÀ» ÁÙÀÌ°í º¹ÀâÇÑ ¸ê±Õ °úÁ¤À» °ÅÄ¡Áö ¾Ê°íµµ °¨¿° À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÏȸ¿ë ³»½Ã°æÀº ºñ¿ë È¿À²¼º°ú ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ´Â ´É·ÂÀ¸·Î ÀÎÇØ ±â°üÁö ³»½Ã°æ°ú ºñ´¢±â°ú¿¡¼ Å« È£ÀÀÀ» ¾ò°í ÀÖ½À´Ï´Ù.
¼¼°è¿¡¼ ¾Ï, ƯÈ÷ ¼Òȱâ¾Ï°ú ´ëÀå¾ÏÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ³»½Ã°æ ½Ã¼úÀÌ ¾ÏÀÇ ¹ß°ß, ¸ð´ÏÅ͸µ ¹× Ä¡·á¸¦ À§ÇÑ ÃÖÀü¼± ¼Ö·ç¼ÇÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ³»½Ã°æ ±â¼úÀº Á¾¾ç Á¦°Å, »ý°Ë äÃë ¹× »óÅ ÃßÀû¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Á¶±â ¾Ï Áø´ÜÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÷´Ü ³»½Ã°æ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.
¿ëµµº°·Î º¹°°æ °Ë»ç´Â 2024³â 54¾ï ´Þ·¯ ½ÃÀå °¡Ä¡¸¦ °¡Áö¸ç 2025-2034³â°£ ¿¬Æò±Õ 6.5%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º¹°°æ°ú °°Àº ÃÖ¼Òħ½ÀÀû ±â¼úÀº ÀÔ¿ø ±â°£ ´ÜÃà, ¿Ü°úÀû ¿Ü»ó °¨¼Ò, ȸº¹ ±â°£ ´ÜÃà°ú °ü·ÃÇÏ¿© ´õ ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ´ã³¶ ÀýÁ¦¼ú¿¡¼ ºñ¸¸ ¼ö¼ú¿¡ À̸£±â±îÁö ȯÀÚ¿Í ¿Ü°úÀÇ»ç ¸ðµÎ ÀÌ·¯ÇÑ Á¢±Ù¹ýÀ» ¼±È£ÇÏ´Â °æÇâÀÌ ¶Ñ·ÇÇØÁö°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼ ºñ¸¸À²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó üÁß °¨·® ¼ö¼ú °Ç¼öµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, º¹°°æ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´õ ¸¹Àº ÀÇ»çµéÀÌ ½Ã¹Ä·¹ÀÌ¼Ç ÇÁ·Î±×·¥ ¹× Àåºñ Á¦Á¶¾÷ü¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇØ º¹°°æ ¼ö¼ú¿¡ ´ëÇÑ ±³À°À» ¹Þ°í ÀÖÀ¸¸ç, ¼÷·ÃµÈ Àü¹®°¡ÀÇ °¡¿ë¼ºÀÌ Çâ»óµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è¿¡¼ º¹°°æ ¼ö¼úÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é 2024³â¿¡´Â º´¿øÀÌ ¾ÐµµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, 2034³â¿¡´Â 348¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º´¿øÀº Áø´Ü ¹× ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÃÖ÷´Ü ³»½Ã°æ ½Ã½ºÅÛÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ÀÌµé ±â°üÀº ƯÈ÷ À§Àå ¹× ¾Ï °ËÁøÀÇ °æ¿ì Áúº´ÀÇ Á¶±â ¹ß°ßÀ» À§ÇØ ³»½Ã°æ °Ë»ç¸¦ äÅÃÇϵµ·Ï Àå·ÁÇÏ´Â Á¤Ã¥Àû Àμ¾Æ¼ºê¿Í º¸Çè Àû¿ëÀ» ÅëÇØ ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù. º´¿øÀº ¿î¿µ ºñ¿ëÀ» ÃÖÀûÈÇÏ¸é¼ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ Áö¼ÓÀûÀ¸·Î ÀÎÇÁ¶ó¸¦ ¾÷±×·¹À̵åÇϰí ÀÖ½À´Ï´Ù. Àå±â ÀÔ¿øÀÇ Çʿ伺À» ÁÙ¿©ÁÖ´Â ³»½Ã°æ °Ë»ç´Â ÀÌ·¯ÇÑ ¸ñÀû¿¡ ºÎÇÕÇÕ´Ï´Ù. Á÷¿ø ±³À° ¹× ±â¼ú ¾÷µ¥ÀÌÆ®¿¡ ÅõÀÚÇÔÀ¸·Î½á º´¿øÀº ³»½Ã°æ ½Ã¼úÀÇ Ãֽа³¹ß¿¡ ÀûÀÀÇÏ¸é¼ ³ôÀº ¼öÁØÀÇ ÀÇ·á ¼ºñ½º¸¦ À¯ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù.
¹Ì±¹ ³»½Ã°æ °Ë»ç ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÀ¸¸ç, 2021³â 92¾ï ´Þ·¯¿¡¼ 2024³â 104¾ï ´Þ·¯·Î Áõ°¡ÇßÀ¸¸ç, 2025-2034³â ¿¬Æò±Õ 6.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü°ú Á¤È®ÇÑ Áø´Ü ÅøÀÇ Çʿ伺ÀÌ ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼Òȱâ ÁúȯÀ¸·Î Áø´Ü¹Þ´Â ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù Áøº¸µÇ°í ´ú ħ½ÀÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÃÀåÀº ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ ºñ¿ë È¿À²¼ºÀ» À¯ÁöÇÏ¸é¼ ½Ã¼ú °á°ú¸¦ °³¼±Çϱâ À§ÇØ ³ë·ÂÇÔ¿¡ µû¶ó °è¼Ó ÁøÈÇϰí ÀÖ½À´Ï´Ù.
°æÀï ±¸µµ´Â ±â¼ú Çõ½Å, Á¦ÈÞ, Á¦Ç°ÀÇ ´Ù¾çÈ¿¡ ÀÇÇØ Á¤Àǵ˴ϴÙ. Stryker Corporation, Olympus Corporation, Boston Scientific, Karl Storz, Medtronic µîÀÇ ±â¾÷ÀÌ ½ÃÀå Á¡À¯À² ¾à 42-45%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ¾÷°è ¼±µÎÁÖÀÚµéÀº AI, ·Îº¿°øÇÐ, ÷´Ü ¿µ»óó¸® ±â¼úÀ» ÅëÇÕÇÑ Â÷¼¼´ë ³»½Ã°æ Ç÷§Æû¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇÏ¿© ÀÓ»óÀû ¼º´ÉÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Àü·«Àû Á¦ÈÞ¿Í ÀμöÇÕº´Àº ¼¼°è ÁøÃâ°ú ÁøÈÇÏ´Â ÀÇ·á±â±â ½ÃÀå¿¡¼ ÀÔÁö¸¦ °ÈÇϱâ À§ÇÑ Áß¿äÇÑ Àü·«À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
The Global Endoscopy Market was valued at USD 29.5 billion in 2024 and is estimated to grow at a CAGR of 6.9% to reach USD 56.9 billion by 2034. Market growth is being shaped by a combination of medical advancements, changing healthcare priorities, and rising disease burdens across the globe. The rising demand for less invasive treatment options and increased utilization of endoscopy for both diagnostic and therapeutic purposes are contributing significantly to market expansion. The market is witnessing consistent momentum due to growing healthcare spending, aging populations, and the rising incidence of chronic and gastrointestinal illnesses worldwide. Moreover, a shift toward early diagnosis and the growing focus on preventive care have led to higher adoption of endoscopic procedures in both public and private healthcare settings. Healthcare systems across the globe are investing in advanced endoscopic technologies that support accurate diagnostics, faster patient recovery, and lower hospitalization costs.
In 2024, the endoscopes segment accounted for the highest market share, generating USD 14.5 billion in revenue. The demand for high-performance imaging and procedural tools continues to accelerate, driven by improvements in visual clarity, maneuverability, and integration of smart features like robotics and AI. These technological advancements are transforming how physicians perform internal examinations, enabling quicker and more precise diagnoses. Compact, flexible, and lightweight endoscopes are now preferred by specialists for reaching anatomical areas that were previously inaccessible. Enhanced usability, reduced patient discomfort, and superior clinical outcomes are strengthening the position of endoscopes in routine practice.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $29.5 Billion |
Forecast Value | $56.9 Billion |
CAGR | 6.9% |
Another contributing factor is the growing preference for single-use and disposable endoscopic tools, which are becoming popular in outpatient and ambulatory settings. These devices help limit the risk of infection and eliminate the need for complex sterilization processes. Single-use endoscopes, in particular, are gaining traction in bronchoscopy and urology due to their cost-efficiency and ability to improve safety for both patients and practitioners.
The rising global burden of cancer, particularly gastrointestinal and colorectal cancers, is driving the need for endoscopic procedures as a frontline solution for detection, monitoring, and treatment. Endoscopic techniques are widely used for tumor removal, biopsy collection, and condition tracking. As awareness about the benefits of early cancer diagnosis grows, the demand for advanced endoscopy solutions continues to surge.
Among the various applications, laparoscopy held a market value of USD 5.4 billion in 2024 and is projected to grow at a CAGR of 6.5% between 2025 and 2034. Minimally invasive techniques like laparoscopy are gaining broader acceptance due to their association with shorter hospital stays, lower surgical trauma, and faster recovery periods. Patients and surgeons alike are showing a clear preference for these approaches in procedures ranging from gallbladder removal to bariatric surgeries. With the increasing rate of obesity worldwide, the number of weight-loss surgeries is rising, further supporting the demand for laparoscopic instruments. As more practitioners receive training in laparoscopy through simulation programs and partnerships with device manufacturers, the availability of skilled professionals is improving, which further drives adoption on a global scale.
In terms of end users, hospitals held the dominant position in 2024 and are projected to reach USD 34.8 billion by 2034. Hospitals are increasingly equipped with state-of-the-art endoscopic systems to meet the rising demand for diagnostics and surgical procedures. These institutions benefit from policy incentives and insurance coverage that promote the adoption of endoscopy for early disease detection, especially in cases of gastrointestinal and cancer screenings. Hospitals are continuously upgrading their infrastructure to enhance patient outcomes while optimizing operational costs. Endoscopy procedures, which reduce the need for extended hospital stays, align well with this objective. Investments in staff training and technology updates ensure that hospitals maintain high standards of care while adapting to the latest developments in endoscopic procedures.
The endoscopy market in the United States has shown consistent growth, rising from USD 9.2 billion in 2021 to USD 10.4 billion in 2024. It is expected to grow at a CAGR of 6.1% from 2025 to 2034. The high prevalence of chronic diseases and the need for precise diagnostic tools are major drivers behind this growth. An increasing number of patients are being diagnosed with gastrointestinal disorders, prompting the need for more advanced and less invasive solutions. The U.S. market continues to evolve as healthcare providers seek to improve procedural outcomes while maintaining cost efficiency.
The competitive landscape is defined by innovation, partnerships, and product diversification. Companies like Stryker Corporation, Olympus Corporation, Boston Scientific, Karl Storz, and Medtronic command approximately 42%-45% of the market share. These industry leaders are actively investing in next-gen endoscopic platforms that integrate AI, robotics, and advanced imaging to elevate clinical performance. Strategic collaborations and acquisitions remain key tactics for broadening global reach and strengthening their position in the evolving medical device landscape.